Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Øvre ekstremitetsrobotassistert terapi hos pasienter med Guillain-Barré syndrom (RAUL-Project)

15. september 2026 oppdatert av: I.R.C.C.S. Fondazione Santa Lucia

Effekter av robotassistert terapi for funksjonell utvinning av øvre lemmer hos pasienter med Guillain-Barré syndrom: en randomisert kontrollert prøvelse

Guillain-Barré Syndrome is an immune-mediated polyradiculoneuropathy, with around 100,000 new cases reported worldwide annually.

The aim of this double-blind randomized controlled trial with a SHAM control group is to evaluate the effects of robot-assisted therapy, integrated with conventional therapy, on upper limb motor recovery in patients with GBS.

Studieoversikt

Detaljert beskrivelse

Guillain-Barré Syndrome is a leading cause of acute flaccid paralysis, presenting with limb weakness and hyporeflexia or areflexia. Guillain-Barré Syndrome is an immune-mediated polyradiculoneuropathy, with around 100,000 new cases reported worldwide annually. This study aims to assess the effectiveness of a robot-assisted rehabilitation treatment for upper limb motor recovery in patients with Guillain-Barré Syndrome. A double-blind randomized trial will be conducted, where the experimental group will undergo actual robotic rehabilitation sessions, while the control group will perform sessions in which the robot will carry out simple mobilization, comparable to traditional interventions. This approach will help maintain participant blinding. Patients will be evaluated before and after treatment, and with two follow-up assessments 60 and 90 days after therapy initiation. Evaluations will include muscle recruitment and autonomy in daily living activities.

Studietype

Intervensjonell

Registrering (Antatt)

62

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Lazio
      • Rome, Lazio, Italia, 00179
        • IRCCS Santa Lucia Foundation

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Diagnosis of Guillan-Barré Syndrome;
  2. UL motor impairment (0-4 in the Medical Research Council scale);
  3. sub-acute phase (until 180 days);
  4. Patients able to maintain the sitting position.

Exclusion Criteria:

  1. Concomitant neurological, orthopedic, metabolic, and oncological diseases;
  2. Cognitive impairment assessed with the Mini Mental State Examination (score under 24 points);
  3. Visual deficit;
  4. Hearing disorders.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Active-assisted therapy with an upper limb robotic exoskeleton

Patients will receive upper limb neurorehabilitation training using a robotic exoskeleton administered by the therapist. The assistance provided by the device is adjusted based on the maximum force (as a percentage of the upper limb's weight) the robot needs to exert to assist the patient's movements. The computer-robot interface is designed to offer various exergames that require specific upper limb movements.

All movements performed by the patient using the exoskeleton will provide immediate audiovisual feedback on the computer screen. The training will consist of 20 sessions, with five 45-minute sessions per week.

Patients will undergo 20 session of 45 minutes each with an exoskeleton for upper limb rehabilitation. The assistance provided by the device is adjusted based on the maximum force (as a percentage of the upper limb's weight) the robot needs to exert to assist the patient's movements. Each session will include exercises designed to improve the range of motion (ROM) of the shoulder, elbow, wrist, and enhance hand coordination. The training parameters, such as difficulty level, duration, and visual stimuli, will be adjusted based on the patient's residual abilities. The selected exercises may involve movements of a single joint along one axis, combined movements of a single joint around 2 or 3 axes, selective exercises for the opening and closing hand, or multi-joint exercises. All exercises will be realized with audiovisual feedback.

Aktiv komparator: Passive mobilization with an upper limb robotic exoskeleton

Patients will undergo a neurorehabilitation intervention with a SHAM treatment under the guidance of the experimental therapist.

Patients will undergo 20 session of 45 minute of a neurorehabilitation intervention with a SHAM treatment under the guidance of the experimental therapist. This will involve passive mobilization using the exoskeleton for the upper limb, without any audiovisual feedback. They will not realize any active movement during the training.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Fugl-Meyer Assessment scale for Upper Extremity (FMAUE)
Tidsramme: Baseline (t0); 30 days (t1); 60 days (t2); 90 days (t3).

THE FMAUE will be used to assess the change in the motor and sensory functions of the upper limb. The FMAUE included five domains: motor functioning, sensitivity, coordination, range of motion and pain. The score ranging from 0 to 66 points, a higher score corresponds to a better function of the upper limb.

Baseline (t0); 30 days (t1); 60 days (t2); 90 days (t3).

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The 36-Item Short-Form Health Survey (SF-36)
Tidsramme: Baseline (t0); 30 days (t1); 60 days (t2); 90 days (t3).

The SF-36 will be used to assess the change in health-related quality of life. The SF-36 is organized into 8 different domains that are divided into physical components (Physical functioning, limitations due to physical problems, bodily pain and general perceptions of health status) and mental components (Social functioning, general mental health, limitations due to emotional problems and vitality). Each of the 8 domain scores, added together, is linearly transformed on a scale from 0 to 100, where 0 equals negative health and 100 equals positive health.

Baseline (t0); 30 days (t1); 60 days (t2); 90 days (t3).
modified Barthel Index (mBI)
Tidsramme: Baseline (t0); 30 days (t1); 60 days (t2); 90 days (t3).

The mBI will be used to assess the change in the autonomy of patients during their activities of daily living. This scale has a score ranging from 0 to 100 points, a higher score corresponds to a better performance in the activities of daily living.

Baseline (t0); 30 days (t1); 60 days (t2); 90 days (t3).
ABILHAND
Tidsramme: Baseline (t0); 30 days (t1); 60 days (t2); 90 days (t3).

The ABILHAND will be used to assess manual dexterity. The ABILHAND is a questionnaire-based assessment tool that measures the difficulty a patient perceives in using their hands to perform manual operations and activities in daily living. It assesses upper limb functionality. It has nonlinear logit values ranging from 1.72 to -2.18.

Baseline (t0); 30 days (t1); 60 days (t2); 90 days (t3).
The Medical Research Council scale (MRC)
Tidsramme: Baseline (t0); 30 days (t1); 60 days (t2); 90 days (t3).

The MRC will be used to assess muscle strength. The score ranges from 0 to 5 where 0 equals no muscle recruitment and 5 normal muscle force.

Baseline (t0); 30 days (t1); 60 days (t2); 90 days (t3).
The nine hole peg test (NHPG).
Tidsramme: Baseline (t0); 30 days (t1); 60 days (t2); 90 days (t3).

The NHPG will be used to assess fine manual dexterity. The NHPT consists of a square board with 9 pegs. At one end of the board are holes to insert the pegs, and at the other end is a shallow round plate to store the extracted pegs. The NHPT is administered by asking the patient to take the pegs from a container, one by one, and insert them into the holes on the board, as quickly as possible.

Baseline (t0); 30 days (t1); 60 days (t2); 90 days (t3).
Grip strength
Tidsramme: Baseline (t0); 30 days (t1); 60 days (t2); 90 days (t3).

Grip strength will be assessed using a manual digital dynamometer. The maximum strength of the whole hand will be recorded for three times without feedback (with the patient sitting with his back to the monitor).

Baseline (t0); 30 days (t1); 60 days (t2); 90 days (t3).

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Mini-Mental State Examination (MMSE)
Tidsramme: T0 (Baseline)

MMSE is a widely used psychometric tool in clinical settings to assess cognitive function. It is employed to detect cognitive impairments, monitor the progression of neurodegenerative diseases such as Alzheimer disease, and evaluate the severity of cognitive decline.

The test consists of a series of questions and tasks that assess various cognitive domains, including orientation in time and space, memory, attention, language, and the ability to follow simple commands.

T0 (Baseline)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studiestol: Alex Martino Cinnera, PhD, IRCCS Santa Lucia Foundation
  • Studiestol: Diego Piatti, BSc, IRCCS Santa Lucia Foundation
  • Studieleder: Laura Casagrande Conti, MSc, IRCCS Santa Lucia Foundation
  • Studieleder: Martina D Arienzo, BSc, IRCCS Santa Lucia Foundation

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. oktober 2024

Primær fullføring (Antatt)

1. oktober 2026

Studiet fullført (Antatt)

1. oktober 2027

Datoer for studieregistrering

Først innsendt

26. september 2024

Først innsendt som oppfylte QC-kriteriene

30. september 2024

Først lagt ut (Faktiske)

1. oktober 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-delingstidsramme

2024/10/01

Tilgangskriterier for IPD-deling

on resonable request to the study' PI

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere